Dr. Hong Hu 胡鸿
Chief Physician
Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive surgical and multidisciplinary comprehensive treatment for benign and malignant chest tumors.
Dr. Hu is Chief Physician and Deputy Director of the Department of Thoracic Surgery, and Executive Deputy Director of the Fudan University Chest Tumor Institute at Fudan University Shanghai Cancer Center. Graduating from Shanghai Medical University in July 1999, Dr. Hu has extensive clinical experience in the multidisciplinary comprehensive treatment of chest tumors, with a focus on surgery.
Professional roles
- Member, Esophageal Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member and Secretary-General, Lung Cancer Professional Committee, Shanghai Anti-Cancer Association
- Member, Esophageal Cancer Professional Committee, Shanghai Anti-Cancer Association
- Standing Committee Member, Rehabilitation Management Professional Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Hu Hong). Papers usually list the name as Hong Hu or Hu H.
Selected publications
96 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2026 (first author): GNL3L-LMNB1 signaling axis promotes lung squamous cell carcinoma growth and ferroptosis resistance via NF-κB activation. PubMed 42444932
- BMC Cancer, 2025 (senior author): Identification and validation of a DNA methylation-block prognostic model in non-small cell lung cancer patients. PubMed 40468278
- Immunotargets Ther, 2023 (senior author): NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. PubMed 38075489
- Cancer Med, 2021 (senior author): Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients. PubMed 34664796
- Front Oncol, 2020 (senior author): Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients. PubMed 33585249
- Eur J Cardiothorac Surg, 2012 (first author): Modifications in retrosternal reconstruction after oesophagogastrectomy may reduce the incidence of anastomotic leakage. PubMed 22345283
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion